HealthEquity management to meet virtually with KeyBanc » 06:5706/2406/24/21
Virtual Meeting to be…
Virtual Meeting to be held on June 29 hosted by KeyBanc.
|Over a week ago|
HealthEquity management to meet virtually with Oppenheimer » 11:4706/1106/11/21
Virtual Meeting to be…
Virtual Meeting to be held on June 11 hosted by Oppenheimer.
HealthEquity price target raised to $90 from $85 at Raymond James » 07:5106/1006/10/21
Raymond James analyst C.…
Raymond James analyst C. Gregory Peters raised the firm's price target on HealthEquity to $90 from $85 and keeps a Strong Buy rating on the shares. The stock has traded down ~5% since reporting Q1 results due in part to reporting lower than expected service revenue as the company's commuter business continues to be impacted by COVID restrictions and the WFM environment, Peters tells investors in a research note.
HealthEquity updates business outlook to exclude Further acquisition expenses » 09:1706/0806/08/21
HealthEquity announced an…
HealthEquity announced an updated business outlook, superseding the business outlook announced by HealthEquity on June 7. The updated business outlook is being issued to exclude anticipated merger integration expenses related to the Further acquisition that were included in the previously announced business outlook. Updated business outlook: For FY22, management expects revenues of $755M-$765M. Its outlook for net loss is between $12M-$8M up from net loss of $19M-$15M, resulting in net loss of 14c-10c per diluted share, up from net loss of 23c-18c per diluted share. Its outlook for non-GAAP net income is between $122M-$126M, resulting in non-GAAP net income per diluted share of $1.45-$1.50. Management expects Adjusted EBITDA of $241M-$247M. This outlook does not include any potential impact from the acquisitions of Further or the Fifth Third Bank HSA portfolio.
HealthEquity price target raised to $85 from $82 at Cantor Fitzgerald » 07:0706/0806/08/21
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Steven Halper raised the firm's price target on HealthEquity to $85 from $82 and keeps an Overweight rating on the shares following the company's Q1 results. In FY22, the company continues to face headwinds from COVID, including sales deferrals for its HSA/CDB platform as well as continued lower revenue from commuter programs, but Halper tells investors in a research note that these headwinds are likely to ease later this year as the economy reopens. The analyst is confident company's ability to return to double-digit revenue growth in FY23 and beyond.
Fly Intel: After-Hours Movers » 18:3106/0706/07/21
SFIX, REVG, MRVL, CYCN, SLQT, CHS, COUP, HQY, PLBY, APR, LESL, MARA, KDP, RIOT, ETSY
Check out this evening's…
HealthEquity raises FY22 EPS view to $1.45-$1.50 from $1.37-$1.42 » 16:1006/0706/07/21
Consensus $1.41. Raises…
Consensus $1.41. Raises FY22 revenue view to $755M-$765M from $750M-$760M, consensus $755.51M. The company said, "For the fiscal year ending January 31, 2022, management expects revenues of $755 million to $765 million. Its outlook for net loss is between $19 million and $15 million, resulting in net loss of $0.23 to $0.18 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $122 million and $126 million, resulting in non-GAAP net income per diluted share of $1.45 to $1.50 (based on an estimated 84 million diluted weighted-average shares outstanding). Management expects Adjusted EBITDA of $241 million to $247 million."
HealthEquity reports Q1 EPS 38c, consensus 32c » 16:0606/0706/07/21
Reports Q1 revenue…
Reports Q1 revenue $184.2M, consensus $180.34M. "Our fiscal year 2022 is off to a fast start with early sales wins, two material acquisition agreements in our core HSA business, and the new Luum mobility benefits platform helping clients return to work," said Jon Kessler, President and CEO of HealthEquity. "We believe our total solution is well-positioned to deliver substantial growth through the economy's reopening and recovery."
|Over a month ago|
HealthEquity resumed with an Overweight at JPMorgan » 07:2104/2904/29/21
JPMorgan analyst Anne…
JPMorgan analyst Anne Samuel resumed coverage of HealthEquity with an Overweight rating and $82 price target. The analyst recommends names in the Healthcare IT space that are "well positioned around the shift to the consumer with fundamental market drivers and differentiated offerings," while positioning away from the electronic medical record space "which faces market maturation." Phreesia (PHR) and Progyny (PGNY) are her favorite ways to play the space.
HealthEquity management to meet virtually with Truist » 04:5504/2304/23/21
Virtual Meeting to be…
Virtual Meeting to be held on April 21 hosted by Truist.